# Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S

> **NCT03615911** · PHASE1 · COMPLETED · sponsor: **Marylyn Addo** · enrollment: 26 (actual)

## Conditions studied

- MERS (Middle East Respiratory Syndrome)

## Interventions

- **BIOLOGICAL:** vaccine candidate MVA-MERS-S

## Key facts

- **NCT ID:** NCT03615911
- **Lead sponsor:** Marylyn Addo
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2019-04-15
- **Final completion:** 2019-05-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615911, "Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03615911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*